CA2615491C - Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps - Google Patents

Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps Download PDF

Info

Publication number
CA2615491C
CA2615491C CA2615491A CA2615491A CA2615491C CA 2615491 C CA2615491 C CA 2615491C CA 2615491 A CA2615491 A CA 2615491A CA 2615491 A CA2615491 A CA 2615491A CA 2615491 C CA2615491 C CA 2615491C
Authority
CA
Canada
Prior art keywords
bmp
tumor
preparation
bone morphogenetic
morphogenetic protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2615491A
Other languages
English (en)
French (fr)
Other versions
CA2615491A1 (en
Inventor
Angelo Luigi Vescovi
Brent Allan Reynolds
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
STEMGEN SpA
Original Assignee
STEMGEN SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by STEMGEN SpA filed Critical STEMGEN SpA
Priority to CA2790675A priority Critical patent/CA2790675C/en
Publication of CA2615491A1 publication Critical patent/CA2615491A1/en
Application granted granted Critical
Publication of CA2615491C publication Critical patent/CA2615491C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2615491A 2005-07-19 2006-07-19 Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps Expired - Lifetime CA2615491C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2790675A CA2790675C (en) 2005-07-19 2006-07-19 Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70085905P 2005-07-19 2005-07-19
US60/700,859 2005-07-19
PCT/IB2006/002296 WO2007010394A2 (en) 2005-07-19 2006-07-19 Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2790675A Division CA2790675C (en) 2005-07-19 2006-07-19 Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps

Publications (2)

Publication Number Publication Date
CA2615491A1 CA2615491A1 (en) 2007-01-25
CA2615491C true CA2615491C (en) 2016-11-29

Family

ID=37420973

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2615491A Expired - Lifetime CA2615491C (en) 2005-07-19 2006-07-19 Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps
CA2790675A Expired - Lifetime CA2790675C (en) 2005-07-19 2006-07-19 Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2790675A Expired - Lifetime CA2790675C (en) 2005-07-19 2006-07-19 Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps

Country Status (13)

Country Link
US (2) US9220756B2 (enExample)
EP (2) EP3117833B1 (enExample)
JP (3) JP5189977B2 (enExample)
KR (2) KR101311061B1 (enExample)
AU (1) AU2006271308B2 (enExample)
CA (2) CA2615491C (enExample)
DK (2) DK3117833T3 (enExample)
ES (2) ES2686093T3 (enExample)
HR (1) HRP20181379T1 (enExample)
HU (2) HUE042197T2 (enExample)
NZ (2) NZ565172A (enExample)
PL (2) PL3117833T3 (enExample)
WO (1) WO2007010394A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3117833T3 (en) * 2005-07-19 2019-03-18 Stemgen S P A Inhibition of Tumor-rich Potential of Tumor Stem Cells with LIF
US8361955B2 (en) 2008-02-13 2013-01-29 Dkfz Deutsches Krebsforschungszentrum, Stiftung Des Offentlichen Rechts Methods for treating and preventing brain tumors based on bone morphogenetic proteins
CA2995310A1 (en) 2015-08-25 2017-03-02 Histide Ag Compounds for inducing tissue formation and uses thereof
EP3349778B1 (en) * 2015-09-17 2021-09-01 Histide AG Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof
KR20180050744A (ko) * 2015-09-17 2018-05-23 히스티드 아게 신생물성 세포를 비-신생물성 세포로 전환시키기 위한 약제학적 회합물 및 이것의 용도
KR20180052705A (ko) * 2015-09-17 2018-05-18 히스티드 아게 신생물성 세포를 비-신생물성 세포로 전환시키기 위한 약제학적 회합물 및 이것의 용도
WO2017046226A2 (en) * 2015-09-17 2017-03-23 Histide Ag Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof.
CA2998677A1 (en) * 2015-09-17 2017-03-23 Histide Ag Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof
WO2020138503A1 (ja) * 2018-12-28 2020-07-02 国立大学法人 東京大学 神経膠腫の治療および予防剤、脳腫瘍の悪性度のマーカーおよび脳腫瘍の予後マーカー、脳腫瘍の悪性度および予後の判定方法並びに腫瘍増殖を抑制する抗体
WO2026022122A1 (en) * 2024-07-23 2026-01-29 Eos Research Sa Checkpoint inhibitors in the treatment of glioblastoma multiforme

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
GB9004890D0 (en) * 1990-03-05 1990-05-02 Heath John K Leukaemia inhibitory factor
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
CA2104576C (en) * 1991-12-24 1997-04-15 George Kannourakis A method for the treatment of tumours and sarcomas
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US7592428B1 (en) * 1992-11-17 2009-09-22 Ludwig Institute For Cancer Research Antibodies which bind specifically to activin receptor like kinases
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
EP0756628B1 (en) * 1994-04-29 2007-11-14 Curis, Inc. Morphogenic protein-specific cell surface receptors and uses therefor
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US6281015B1 (en) * 1994-12-16 2001-08-28 Children's Medical Center Corp. Localized delivery of factors enhancing survival of transplanted cells
US20010053371A1 (en) * 1999-01-07 2001-12-20 Waldemar Debinski Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13
US5804162A (en) 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US6036920A (en) 1996-05-09 2000-03-14 3-Dimensional Pharmaceuticals, Inc. Microplate thermal shift assay apparatus for ligand development and multi-variable protein chemistry optimization
JP4892131B2 (ja) * 1998-11-13 2012-03-07 ストライカー コーポレイション 癌の症状を緩和する方法
EP1246617B1 (en) * 1999-12-06 2006-09-13 Rhode Island Hospital Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of ovarian cancer
US20030162700A1 (en) * 2000-03-03 2003-08-28 Shipham Kylie Ann-Maree Method of treatment
WO2005026382A1 (en) 2003-09-12 2005-03-24 Stemcell Technologies Inc. Neural colony forming assay
JP2005098727A (ja) 2003-09-22 2005-04-14 Hosiden Corp 振動センサ
CA2546465A1 (en) 2003-12-05 2005-06-23 The Board Of Trustees Of The Leland Stanford Junior University Identification, isolation and elimination of cancer stem cells
EP2789342A1 (en) * 2004-06-17 2014-10-15 Thrasos Innovation, Inc. TDF-related compounds and analogs thereof
DK3117833T3 (en) * 2005-07-19 2019-03-18 Stemgen S P A Inhibition of Tumor-rich Potential of Tumor Stem Cells with LIF
ES2363358B1 (es) * 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
JO3421B1 (ar) 2011-06-20 2019-10-20 H Lundbeck As طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية
WO2015050844A1 (en) * 2013-10-01 2015-04-09 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds

Also Published As

Publication number Publication date
EP1904093B1 (en) 2018-06-13
US9737589B2 (en) 2017-08-22
KR101311061B1 (ko) 2013-09-25
CA2615491A1 (en) 2007-01-25
HRP20181379T1 (hr) 2018-11-16
EP3117833B1 (en) 2019-01-23
EP3117833A1 (en) 2017-01-18
KR20120125990A (ko) 2012-11-19
JP2012107063A (ja) 2012-06-07
ES2686093T3 (es) 2018-10-16
US20100167999A1 (en) 2010-07-01
KR101338533B1 (ko) 2013-12-12
JP2015057452A (ja) 2015-03-26
JP2009502771A (ja) 2009-01-29
NZ565172A (en) 2012-12-21
WO2007010394A3 (en) 2007-08-30
PL1904093T3 (pl) 2018-12-31
AU2006271308B2 (en) 2012-12-20
EP1904093A2 (en) 2008-04-02
KR20080082595A (ko) 2008-09-11
JP5189977B2 (ja) 2013-04-24
AU2006271308A1 (en) 2007-01-25
ES2710601T3 (es) 2019-04-26
WO2007010394A2 (en) 2007-01-25
HUE040063T2 (hu) 2019-02-28
CA2790675A1 (en) 2007-01-25
DK1904093T3 (en) 2018-09-03
DK3117833T3 (en) 2019-03-18
JP5891068B2 (ja) 2016-03-22
CA2790675C (en) 2016-12-20
US9220756B2 (en) 2015-12-29
NZ598031A (en) 2013-11-29
US20160228511A1 (en) 2016-08-11
PL3117833T3 (pl) 2019-06-28
HUE042197T2 (hu) 2019-06-28

Similar Documents

Publication Publication Date Title
US9737589B2 (en) Inhibition of the tumorigenic potential of tumor stem cells by LIF and BMPs
JP6523910B2 (ja) 腫瘍幹細胞におけるｅｐｈ受容体発現
Irvine et al. Deletion of Wntless in myeloid cells exacerbates liver fibrosis and the ductular reaction in chronic liver injury
Berger et al. Co-regulated decrease of Neurokinin-1 receptor and Hemokinin-1 gene expression in monocytes and macrophages after activation with pro-inflammatory cytokines
AU2012202157B2 (en) Inhibition of the tumorigenic potential of tumor stem cells by LIF and BMPS
JP2021514364A (ja) 白斑を処置するための方法及び組成物
HK1233494A1 (en) Inhibition of the tumorigenic potential of tumor stem cells by lif
HK1233494A (en) Inhibition of the tumorigenic potential of tumor stem cells by lif
HK1233494B (en) Inhibition of the tumorigenic potential of tumor stem cells by lif
HK1117414B (en) Inhibition of the tumorigenic potential of tumor stem cells by bmp-4
HK1117414A (en) Inhibition of the tumorigenic potential of tumor stem cells by bmp-4
Frazer et al. BMP antagonist Gremlin 2 regulates hippocampal neurogenesis and is associated with seizure susceptibility and anxiety
Viswanathan et al. CNSC-57. HUMAN AND MOUSE PERITUMORAL SLICES DEMONSTRATE MTOR-DEPENDENT GABAERGIC NEURONAL DYSFUNCTION IN GLIOMA
Strehle Neurobiological mechanisms of mammary tumor-induced neuroinflammation in a female mouse model
US10233240B1 (en) Methods for treating cholestatic liver fibrosis
Battistello PEMFs and cerebral ischemia: the pathways behind their beneficial effects
Almale del Barrio Crosstalk between HGF and TGF-ß signaling pathways in adult liver progenitor cells and hepatocellular carcinoma cells
Dropmann TGF-β2 abundance in mice and men: A successful anti-TGF-β2 strategy in biliary-derived liver disease
Yang The functions of RecQ protein-like 4 and high mobility group box 1 in osteoblast-like cells
Pierre et al. Original Research Article J. cell. Physiol
Zerr Evaluation Neuer Molekularer Ansätze Für Die Behandlung Der Fibrose

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240715

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250528